Drug Shortage Active
PRECEDEX is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
PRECEDEX (dexmedetomidine hydrochloride) by Pfizer is 2 -adrenergic agonist with sedative properties. First approved in 1999.
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
PRECEDEX (dexmedetomidine HCl) is a selective alpha-2 adrenergic agonist indicated for sedation in ICU and perioperative settings. It provides sedation with maintained airway reflexes and reduced opioid requirements through alpha-2 receptor activation in the central nervous system.
Peak-stage product with established hospital ICU/perioperative penetration; stable team supporting mature indication portfolio with limited new revenue drivers.
2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10–300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
A Study to Learn About the Study Medicine - Precedex in Children From Japan.
Precedex Special Investigation (in Pediatric Patients)
Study to Evaluate Hemodynamic Effect of Different Loading Doses of Precedex in Post-surgical Intensive Care Unit (ICU) Patients
Cerebral Perfusion Pressure Using Precedex and Other Sedatives
Worked on PRECEDEX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PRECEDEX offers deep expertise in a mature, specialized injectable sedative franchise with strong hospital relationships and established clinical protocols. This is ideal for professionals focused on maximizing lifecycle value, penetration in critical-care settings, and preparing for post-LOE portfolio transitions.